- Halozyme Therapeutics (NASDAQ:HALO) and argenx (NASDAQ:ARGX) are expanding their existing global collaboration and license agreement that was signed in February 2019.
- Under the expanded deal, argenx gained the ability to exclusively access Halozyme's ENHANZE drug delivery technology for three additional targets upon nomination for a total of up to six targets under the existing and newly expanded collaboration.
- To date, argenx has nominated two targets including the human neonatal Fc receptor FcRn and complement component C2.
- https://seekingalpha.com/news/3620001-halozyme-expands-license-agreement-argenx-for-enhanze-technology
Tuesday, October 6, 2020
Halozyme expands license agreement with argenx
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.